The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms (Glucose-AF)
Primary Purpose
Atrial Fibrillation, Type 2 Diabetes
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
High-intensity interval training + standard care
Sponsored by
About this trial
This is an interventional other trial for Atrial Fibrillation focused on measuring high-intensity interval training, glycemic variability, continuous glucose monitoring system
Eligibility Criteria
Inclusion Criteria:
- non-permanent atrial fibrillation
- diagnosed with type 2 diabetes
- non-smokers
- able to perform a symptom-limited cardiopulmonary exercise test (CPET)
- rate controlled with a resting ventricular rate of ≤110 beats per minute
Exclusion Criteria:
- uncontrolled type 2 diabetes (A1C >10 % or presence of type 2 diabetes-related complications
- on exogenous insulin
- unstable diagnosed angina
- diagnosed severe mitral or aortic stenosis
- diagnosed hypertrophic obstructive cardiomyopathy with significant obstruction
- presence of self-reported alcohol or substance abuse
- unable to provide written, informed consent
Sites / Locations
- University of Ottawa Heart InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
High-intensity interval training
Standard care
Arm Description
Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
Participants will not participate in on-site supervised exercise sessions.
Outcomes
Primary Outcome Measures
Glucose variability
Change in glucose variability as measured by the continuous glucose monitoring system
Secondary Outcome Measures
Atrial fibrillation symptom severity
Changes in atrial fibrillation symptom severity as assessed by the University of Toronto Atrial Fibrillation Severity Scale (AFSS). The questions include: AF frequency; overall severity; duration of AF episodes; frequency of hospitalization, visits to emergency room and specialist; and overall well-being (Likert scale with 1 indicating "worst possible life" to 10 indicating "best possible life").
Atrial fibrillation-related quality of life
Change in the AF-related quality of life will be assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire.The questionnaire includes Likert scale ranging from 1 to 7. The score will be transformed to a 0 to 100 scale where higher score represents better AF-related quality of life.
General quality of life
Change in general quality of life will be assessed by the Short Form 36 Health Survey Questionnaire (SF-36). It yields an 8-scale profile of functional health and well-being scores, with higher scores indicating better quality of life.
Sleep quality
Change in the sleep quality will be assessed by the 3-day sleep diary and Pittsburgh Sleep Quality index (PSQI). A global PSQI score ranges from 0 to 21 with higher scores indicating worse sleep quality.
Changes in blood biomarker concentrations
Changes in the blood biomarker concentrations linked to glucose variability and AF symptom severity.
Full Information
NCT ID
NCT04190212
First Posted
November 29, 2019
Last Updated
September 5, 2023
Sponsor
Ottawa Heart Institute Research Corporation
1. Study Identification
Unique Protocol Identification Number
NCT04190212
Brief Title
The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms
Acronym
Glucose-AF
Official Title
Examining the Role of High-intensity Interval Training on Glucose Variability and Symptomatology: A Novel Approach for Patients With Atrial Fibrillation and Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 18, 2021 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
January 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ottawa Heart Institute Research Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The incidence of atrial fibrillation (AF), the most common heart rhythm disorder, is increasing. The symptoms of AF include: unpleasant heartbeats; difficulty breathing; tiredness; dizziness; and, reduced exercise capacity. Patients with AF have lower quality of life, higher mental distress, and higher risk of heart disease and stroke when compared to the general population. Further, patients with non-permanent AF tend to experience more severe symptoms and substantial reductions in quality of life when compared to patients with permanent AF.
Type 2 diabetes increases the risk of developing AF and accounts for about 20% of patients with non-permanent AF. High blood glucose concentrations and increased blood glucose fluctuations (large and frequent upward and downward blood glucose swings) are commonly seen in type 2 diabetes. Increased blood glucose fluctuations may worsen AF symptoms and quality of life in patients with AF.
Exercise improves quality of life and mental health and reduces risk of developing heart disease and stroke. However, no clinical guidelines for managing AF include exercise. High-intensity interval training (HIIT), a form of exercise that alternates between intense bouts of exercise and less intense recovery periods, is a time-efficient approach to improve blood glucose fluctuations in type 2 diabetes. In healthy individuals and in patients with coronary artery disease, HIIT also improves quality of life and mental health. Currently, the effect of HIIT on blood glucose fluctuations, AF symptom severity and quality of life in patients with AF living with type 2 diabetes is unknown. Also, the links between blood glucose fluctuations and AF symptom severity and quality of life have not been investigated.
Detailed Description
There is a global epidemic of AF, the most common sustained cardiac arrhythmia, and type 2 diabetes (T2D). Given an aging population and physically inactive lifestyles, the prevalence of AF and T2D is expected to increase. AF is a progressive disorder with three principal subtypes: paroxysmal AF (AF that self-terminates within <7 days), persistent AF (AF that lasts >7 days and is terminated by medications or procedures) and permanent AF (patient and treating physician agree not to pursue further intervention). AF-related symptoms are disabling and highly variable, including exercise intolerance, palpitations, breathlessness, fatigue, dizziness and mental distress. Patients with non-permanent AF experience more severe symptoms when compared to those with permanent AF, and suffer from substantial reductions in quality of life (QoL) and increased risk of major cerebrovascular events, cardiovascular events and mortality.
T2D is a risk factor for developing AF and approximately 20% of non-permanent AF patients (i.e. paroxysmal and persistent AF) suffer from this condition. T2D is characterized by insulin resistance and insulin insufficiency leading to high blood glucose concentrations. Inadequate or poor glycemic control leads to increases in glycemic variability (GV, amplitude and frequency of blood glucose oscillations from either high to low or low to high). GV is considered to exacerbate AF symptoms severity by increasing: (1) inflammation; (2) oxidative stress; and, (3) autonomic nervous system dysfunction. Emerging evidence also highlights associations between GV and poor QoL and negative mood in patients with T2D.
High-intensity interval training (HIIT), a form of exercise that involves periods of short, intense exercise bouts interspersed by less intense recovery periods, has emerged as a time-efficient and practical approach to improving GV. Importantly, only 10 HIIT sessions over 2 weeks have been shown to lower GV in patients with T2D. A systematic review (N=50 studies) revealed that HIIT improves insulin resistance and blood glucose control (glycated hemoglobin A1C) when compared to controls (i.e. no exercise) in patients with metabolic syndrome or T2D. HIIT also increases QoL in patients with coronary artery disease (CAD) following 4 weeks of exercise training; reduces inflammatory markers (i.e. interleukin-6 [IL-6] and C-reactive protein [CRP]30) in patients with CAD; attenuates markers of oxidative stress in healthy adults in 3 weeks; and improves cardiac autonomic nervous system function in healthy sedentary men in 2 weeks.
The recent American Diabetes Association guidelines recommend HIIT as a strategy to control blood glucose in patients with T2D. However, neither national nor international clinical guidelines for managing AF include exercise. The absence of exercise from these guidelines in the face of increasing evidence of its physical and mental health benefits reflects a lost opportunity to provide AF patients with better treatment options, particularly those who suffer from concomitant T2D. The effects of HIIT on GV, AF symptom severity and QoL in non-permanent AF patients with T2D are unknown, and the associations between GV and AF symptom severity and QoL remain to be investigated. Examining the impact of HIIT on GV, AF symptom severity and QoL may provide a novel, feasible and time-efficient therapeutic option for non-permanent AF patients with T2D who are searching for better treatment options.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Type 2 Diabetes
Keywords
high-intensity interval training, glycemic variability, continuous glucose monitoring system
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
High-intensity interval training
Arm Type
Experimental
Arm Description
Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
Arm Title
Standard care
Arm Type
No Intervention
Arm Description
Participants will not participate in on-site supervised exercise sessions.
Intervention Type
Behavioral
Intervention Name(s)
High-intensity interval training + standard care
Intervention Description
HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
Primary Outcome Measure Information:
Title
Glucose variability
Description
Change in glucose variability as measured by the continuous glucose monitoring system
Time Frame
From baseline to follow-up after 4-week intervention
Secondary Outcome Measure Information:
Title
Atrial fibrillation symptom severity
Description
Changes in atrial fibrillation symptom severity as assessed by the University of Toronto Atrial Fibrillation Severity Scale (AFSS). The questions include: AF frequency; overall severity; duration of AF episodes; frequency of hospitalization, visits to emergency room and specialist; and overall well-being (Likert scale with 1 indicating "worst possible life" to 10 indicating "best possible life").
Time Frame
From baseline to follow-up after 4-week intervention
Title
Atrial fibrillation-related quality of life
Description
Change in the AF-related quality of life will be assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire.The questionnaire includes Likert scale ranging from 1 to 7. The score will be transformed to a 0 to 100 scale where higher score represents better AF-related quality of life.
Time Frame
From baseline to follow-up after 4-week intervention
Title
General quality of life
Description
Change in general quality of life will be assessed by the Short Form 36 Health Survey Questionnaire (SF-36). It yields an 8-scale profile of functional health and well-being scores, with higher scores indicating better quality of life.
Time Frame
From baseline to follow-up after 4-week intervention
Title
Sleep quality
Description
Change in the sleep quality will be assessed by the 3-day sleep diary and Pittsburgh Sleep Quality index (PSQI). A global PSQI score ranges from 0 to 21 with higher scores indicating worse sleep quality.
Time Frame
From baseline to follow-up after 4-week intervention
Title
Changes in blood biomarker concentrations
Description
Changes in the blood biomarker concentrations linked to glucose variability and AF symptom severity.
Time Frame
From baseline to follow-up after 4-week intervention
Other Pre-specified Outcome Measures:
Title
Link between glucose variability and atrial fibrillation symptom severity
Description
Correlation between glucose variability and atrial fibrillation symptom severity measured by the University of Toronto Atrial Fibrillation Severity Scale (AFSS)
Time Frame
From baseline to follow-up after 4-week intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
non-permanent atrial fibrillation
diagnosed with type 2 diabetes
non-smokers
able to perform a symptom-limited cardiopulmonary exercise test (CPET)
rate controlled with a resting ventricular rate of ≤110 beats per minute
Exclusion Criteria:
uncontrolled type 2 diabetes (A1C >10 % or presence of type 2 diabetes-related complications
on exogenous insulin
unstable diagnosed angina
diagnosed severe mitral or aortic stenosis
diagnosed hypertrophic obstructive cardiomyopathy with significant obstruction
presence of self-reported alcohol or substance abuse
unable to provide written, informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer L Reed, PhD
Phone
6136967392
Email
JReed@ottawaheart.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Tasuku Terada, PhD
Phone
6136967000
Ext
17234
Email
tterada@ottawaheart.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer L Reed, PhD
Organizational Affiliation
Ottawa Heart Institute Research Corporation
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Ottawa Heart Institute
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y4W7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer L Reed, PhD
Phone
6136967392
Ext
67392
Email
jreed@ottawaheart.ca
12. IPD Sharing Statement
Learn more about this trial
The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms
We'll reach out to this number within 24 hrs